Spravato Therapy in Dallas
Covered By Insurance
Spravato therapy, also known as Esketamine for Treatment-Resistant Depression, is a relatively new treatment for depression that has been approved by the US Food and Drug Administration (FDA) in 2019. This treatment has shown promise in treating individuals who have not responded to other depression treatments, such as antidepressant medications and psychotherapy.
Spravato praised as effective treatment for depression
Why Choose PsychDFW for Spravato Therapy.
What We Treat
Learn More About Spravato Therapy
Spravato therapy is only available with a prescription and must be administered under the supervision of a healthcare professional in a healthcare setting. The first step in receiving Spravato therapy is to be evaluated by a healthcare professional to determine if it is an appropriate treatment option. If it is deemed appropriate, the healthcare professional will administer the nasal spray and monitor the individual for any potential side effects. Ketamine has been used for many years as an anesthetic, but it has also shown promise in treating depression. However, due to its potential for abuse and addiction, it is classified as a Schedule III controlled substance by the Drug Enforcement Administration (DEA). Esketamine, on the other hand, has been developed as a form of ketamine that can be used safely and effectively in a clinical setting.
Spravato therapy is designed for individuals who have not responded to other treatments for depression, including antidepressant medications and psychotherapy. It is not a first-line treatment option and is reserved for individuals who have severe, treatment-resistant depression.
The exact mechanism of action of Spravato is not fully understood, but it is thought to work by increasing the availability of certain neurotransmitters in the brain, including glutamate and serotonin. These neurotransmitters are involved in mood regulation, and increasing their availability can improve symptoms of depression.
The mechanism of action of Spravato is not fully understood, but it is believed to work by restoring the balance of certain chemicals in the brain, such as glutamate, which play a role in mood regulation. Spravato is thought to act on the N-methyl-D-aspartate (NMDA) receptor, which is involved in the release of glutamate. By acting on this receptor, Spravato is thought to increase the release of glutamate, which in turn stimulates the growth of new neural connections in the brain, leading to improved mood and decreased depression symptoms.
Like any medication, Spravato therapy can have potential side effects. The most common side effects reported in clinical trials include dizziness, nausea, dissociation, and headache. These side effects are usually mild and temporary, and they typically subside within a few hours after the treatment. However, there is a risk of more serious side effects, such as changes in blood pressure or heart rate, which can be monitored by a healthcare professional during the treatment.
Like all medications, Spravato therapy has potential side effects and risks. Some of the most common side effects reported with Spravato include:
- Dizziness Disorientation
- Increased blood
- Feeling disconnected from reality
- Blurred vision
Some individuals may also experience more serious side effects, such as hallucinations, delusions, and suicidal thoughts. Because of these risks, Spravato is only administered in a healthcare setting and is closely monitored by a healthcare provider.
In addition to these potential side effects, there is also concern about the long-term effects of Spravato therapy, as it is a relatively new treatment option. However, early studies have shown that it is generally safe and well-tolerated when used as directed.
However, it is important to discuss your options with your healthcare provider to determine if it is right for you. Your healthcare provider can help you weigh the benefits and risks of the treatment and determine if it is the best course of action for your individual needs.